Market Place
Sourcing Support
Nymox Announces Trading Resumed and New Listing on OTCQB Market
17 Dec 2024 //
GLOBENEWSWIRE
Nymox Announces Filing of Annual Report
30 Aug 2024 //
GLOBENEWSWIRE
Nymox Annual Report
18 Jul 2024 //
GLOBENEWSWIRE
Nymox Required to Resubmit Application to DKMA
16 Jul 2024 //
GLOBENEWSWIRE
Nymox Reports Victory in Bahamas Litigation Against Terminated Ex-Employees
27 Mar 2024 //
GLOBENEWSWIRE
Nymox December 27 Message to Shareholders
27 Dec 2023 //
GLOBENEWSWIRE
Nymox drama heightens as biotech sues AscellaHealth for $250M
10 Nov 2023 //
FIERCE BIOTECH
Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million
09 Nov 2023 //
GLOBENEWSWIRE
The Committee to Restore Nymox Shareholder Value Provides Factual Update
06 Nov 2023 //
BUSINESSWIRE
NYMOX: California Court Issued A Temporary Restraining Order Enjoining Lanham
03 Nov 2023 //
GLOBENEWSWIRE
Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham
03 Nov 2023 //
GLOBENEWSWIRE
NYMOX Cautions Against Unauthorized Improper Shareholder Meeting
02 Nov 2023 //
GLOBENEWSWIRE
NYMOX Cautions Shareholder Not to Take Calls in Unauthorized Shareholder Meeting
31 Oct 2023 //
GLOBENEWSWIRE
Notice: Nymox Informs Its Shareholders Not to Take Calls
27 Oct 2023 //
GLOBENEWSWIRE
Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review
26 Oct 2023 //
GLOBENEWSWIRE
The Committee to Restore Shareholder Value Sends Letter to Nymox Shareholders
23 Oct 2023 //
BUSINESSWIRE
Nymox responds as the Bahamas Supreme Court Rules in Favor of the Committee
10 Oct 2023 //
BUSINESSWIRE
Bahamas Court Rules in Favor of Committee to Restore Nymox Shareholder Value
05 Oct 2023 //
BUSINESSWIRE
Nymox Announces Submission of New MAA Submission for NYMOZARFEX
25 Sep 2023 //
GLOBENEWSWIRE
Surge of Shareholders Joins The Committee to Restore Nymox Shareholder Value
08 Aug 2023 //
BUSINESSWIRE
Committee to Restore Nymox Shareholder Value Publishes Letters from Attorneys
01 Aug 2023 //
BUSINESSWIRE
Nymox`s ex-CFO was Awarded an Unauthorized and Undisclosed Treasury Directive
31 Jul 2023 //
GLOBENEWSWIRE
Nymox airs dirty laundry about ex-CFO, failed deal proposal
31 Jul 2023 //
FIERCE BIOTECH
Nymox Reports Successful NYMOZARFEX (TM) Prostate Cancer Treatment Trial Results
25 Jul 2023 //
GLOBENEWSWIRE
Nymox Reports on U.S. Patent Issuances
18 Jul 2023 //
GLOBENEWSWIRE
Nymox hits back at mutiny led by former execs
13 Jul 2023 //
FIERCE BIOTECH
Nymox Update
13 Jul 2023 //
GLOBENEWSWIRE
Nymox Announces Appointment Of Patrick Doody as Vice President
12 Jul 2023 //
GLOBENEWSWIRE
Rebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP
10 Jul 2023 //
PR NEWSWIRE
Nymox faces rebellion led by former execs over stalled deal
10 Jul 2023 //
FIERCE BIOTECH
NYMOX Update
07 Jul 2023 //
GLOBENEWSWIRE
Nymox Delisting from NASDAQ
05 Jul 2023 //
GLOBENEWSWIRE
Nymox Provides Corporate Update
03 Apr 2023 //
GLOBENEWSWIRE
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
21 Mar 2023 //
GLOBENEWSWIRE
Nymox Officially Granted Extension to Regain Listing Requirements
15 Mar 2023 //
GLOBENEWSWIRE
Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
15 Feb 2023 //
GLOBENEWSWIRE
NYMOX Appeals Deficiency Letter
06 Jan 2023 //
GLOBENEWSWIRE
NYMOX Updates Shareholders
15 Jul 2022 //
GLOBENEWSWIRE
NYMOX Receives Deficiency Letter from NASDAQ
14 Jul 2022 //
GLOBENEWSWIRE
NYMOX Receives RTF letter from FDA
23 May 2022 //
GLOBENEWSWIRE
Nymox Announces Closing of $6.4 Million Financing
04 Apr 2022 //
GLOBENEWSWIRE
Nymox says $5 M Registered Direct Offering
18 Mar 2022 //
GLOBENEWSWIRE
NYMOX Submits NDA to the FDA for Fexapotide Triflutate
03 Mar 2022 //
GLOBENEWSWIRE
Nymox Pharma reports progress on fexapotide filing; shares down 5%
11 Oct 2021 //
SEEKING ALPHA
NYMOX Provides Current Update
11 Oct 2021 //
GLOBENEWSWIRE
NYMOX Provides Shareholder Update
10 Sep 2021 //
BIOSPACE
Nymox Announces Important New Patent Developments
21 Apr 2020 //
GLOBENEWSWIRE
